Become A Featured Company

Cannabix Set to Begin Trials in BC with New Hire

Ryan Allway

June 13th, 2017

News, Top News

The legalization of cannabis throughout the United States and Canada has been a boon for businesses and consumers, but law enforcement has been struggling to adapt to new challenges facing drug detection. There’s growing evidence that ‘high’ driving has at least some negative side-effects, but there’s no easy way to detect the presence of tetrahydrocannabinol (THC) at road-side until such a point of care device is created.

In this article, we will look at Cannabix Technologies Inc. (CSE: BLO) (OTCQB: BLOZF) and its efforts to develop a highly sensitive marijuana breathalyzer using its patented FAIMS technology.

Forensic Expert Added to Scientific Team

Cannabix Technologies recently announced the addition of Dr. David Hasman to its scientific team. With a PhD in Chemical Physics from the University of California, Dr. Hasman has worked with the British Columbia Institute of Technology’s Forensics Sciences department for several years before eventually forming Procyon Research Inc. to focus on GC/MS and LC/MS/MS method development in forensics, natural products, and environmental disciplines.

Dr. Hasman’s addition to the company’s Florida-Vancouver scientific team will broaden its testing capabilities in Vancouver with human subjects and sets the stage for trials designed to prove the effectiveness of its patented FAIMS device following preliminary human subject testing in March. These earlier studies confirmed that the device is capable of detecting THC levels in real-time using mass spectrometry after inhaling cannabis.

“We are excited to have Dr. Hasman join our Vancouver team as we prepare for trials using the patented FAIMS device with court accepted techniques of mass spectrometry,” said Cannabix Technologies’ Dr. Raj Attariwala. “His expertise in toxicology and forensic mass spec have been instrumental with government toxicology and forensic mass spec have been instrumental with government toxicology labs during the recent fentanyl crisis in BC and his skills will be invaluable as we prepare for trials with the Cannabix marijuana breathalyzer device.”

Working Quickly to Deliver a Device to Law Enforcement

Cannabix Technologies has made tremendous progress over the past several months bringing its alpha version to a beta and beta 2.0 prototype. After preliminary testing on human subjects in March, the company announced that it would be further testing its prototypes by calibrating decay signal intensities with a refined breath collection component. The goal is to create a marijuana breathalyzer that can be used the same way as an alcohol breathalyzer.

In recent months, the company has substantially increased its testing ability with new equipment and staff joining the Vancouver operation. The scientific team has also been developing a new “front end” breath intake system while optimizing the performance, accuracy, and sensitivity of the prototypes. The upcoming scientific trials will edge Cannabix closer to bringing the innovative technology to market for law enforcement.

It’s difficult to overstate the demand for such a device among law enforcement agencies across North America. Roadside breathalyzers would provide law enforcement with immediate feedback and it’s already well understood by the general public and officers. At the moment, police must use invasive blood tests or ineffective mouth swabs as a proxy until this technology is perfected.

“The high resolving power of the FAIMS device with its capability for real-time detection of THC and its metabolic breakdown products will aid in establishing key metrics for measuring in-vivo THC metabolism and should permit detection capabilities similar to that of blood tests,” added Dr. Attariwala. “The current human testing on the FAIMS based Cannabix Marijuana Breathalyzer has shown impressive results thus far.”

Looking Ahead

Cannabix Technologies Inc. (CSE: BLO) (OTCQB: BLOZF) is approaching a key tipping point with its patented FAIMS-based marijuana breathalyzer. With continued testing and optimization in the near-term, Cannabix is well positioned to reach the market at a time when there’s a significant demand across North America.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading